Commercialisation of biotech assets – learning from the pioneers: part fourIn the fourth part of his critical assessment of the options open to biotech companies to commercialising their Share XCommercialisation of biotech assets – learning from the pioneers: part fourhttps://pharmaphorum.com/views-and-analysis/commercialisation-of-biotech-assets-learning-from-the-pioneers-part-four/
Biogen’s multiple sclerosis drug gains further patent protectionBiogen’s multiple sclerosis drug Tecfidera has received a further 10 years of regulatory exclusivity in the European Union Share XBiogen’s multiple sclerosis drug gains further patent protectionhttps://pharmaphorum.com/news/biogen-s-multiple-sclerosis-drug-gains-further-patent-protection/
Spotlight on… blood cancersOur latest ‘spotlight on’ article explores the risks, symptoms and available treatments for patients with blood cancers, such Share XSpotlight on… blood cancershttps://pharmaphorum.com/views-and-analysis/spotlight-on-blood-cancers/
Pfizer, GSK in melanoma partnershipPfizer and GSK have entered into an agreement to explore the anti-cancer efficacy and the safety of GSK’s Share XPfizer, GSK in melanoma partnershiphttps://pharmaphorum.com/news/pfizer-gsk-in-melanoma-partnership/
Pharma digital advertising guidelines that workThe main reason Canadian guidelines are working so well is the fact that pharmaceutical industry personnel wrote them Share XPharma digital advertising guidelines that workhttps://pharmaphorum.com/views-and-analysis/pharma-digital-advertising-guidelines-that-work/
Merck Serono, Biopharm in osteoarthritis research collaborationMerck Serono, the biopharmaceutical division of Merck, and Biopharm GmbH have announced a research collaboration directed towards the Share XMerck Serono, Biopharm in osteoarthritis research collaborationhttps://pharmaphorum.com/news/merck-serono-biopharm-in-osteoarthritis-research-collaboration/
Marketing ExcellencePete West queries the concept of pharmaceutical marketing excellence in our marketing excellence themed month. When I was Share XMarketing Excellencehttps://pharmaphorum.com/views-and-analysis/marketing-excellence/
FDA requests more data on Forest’s schizophrenia drugThe US Food and Drug Administraton (FDA) has issued a complete response letter to New York-based Forest Laboratories Share XFDA requests more data on Forest’s schizophrenia drughttps://pharmaphorum.com/news/fda-requests-more-data-on-forest-s-schizophrenia-drug/
Pharma really can embrace content marketingAre pharma marketers put off by heavy regulations? Ash Rishi believes this is just an excuse in part Share XPharma really can embrace content marketinghttps://pharmaphorum.com/views-and-analysis/pharma-really-can-embrace-content-marketing/
